Welcome to our dedicated page for McKesson news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson stock.
McKesson Corporation reports developments tied to its role as a diversified healthcare services company and major pharmaceutical distributor. Company news commonly covers fiscal results and guidance, dividend declarations, capital allocation, share repurchase activity, and updates across core distribution, oncology and multispecialty, biopharma services, pharmacy technology, and medical-surgical product categories.
McKesson updates also include portfolio actions and governance changes. Recent company materials document the completed divestiture of its Norwegian retail and distribution businesses, marking its exit from European operations, alongside recurring communications about earnings events, healthcare conferences, and leadership succession matters.
McKesson Corporation (MCK) will release its second quarter fiscal 2027 financial results after market close on Wednesday, November 4, 2026.
The company will host a live earnings conference call webcast for investors at 4:30 PM Eastern Time the same day. Live and archived audio of the webcast will be available through McKesson’s Investor Relations website.
McKesson (NYSE: MCK) signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion. Following closing, Precision Medicine Group will be reported within McKesson’s Oncology & Multispecialty segment.
According to McKesson, the acquisition is intended to enhance its clinical research and commercialization services, strengthen clinical trial execution, and broaden clinical service offerings. Precision Medicine Group supports next‑generation drug development with integrated, technology‑enabled services, including biomarker intelligence, lab services, a global clinical research organization, and market access and commercialization support. The transaction is subject to customary closing conditions, including regulatory clearances.
McKesson (NYSE: MCK) has released its fiscal 2027 first quarter financial results, which are available on the company’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.
The company will host a live earnings conference call and webcast for investors on Wednesday, August 5 at 4:30 PM ET. The audio webcast, earnings press release, financial tables, and slide presentation will be available live and archived on the Investor Relations site. Information on future investor events is available at investor.mckesson.com/events-and-presentations.
McKesson (NYSE:MCK) announced that its Board of Directors declared a regular quarterly dividend of $0.94 per share, representing a 15% increase from the prior quarter’s $0.82. The dividend is payable on October 1, 2026, to shareholders of record as of September 1, 2026. This marks McKesson’s tenth consecutive year of dividend growth, which the company links to business strength, disciplined capital allocation, and its focus on long-term shareholder value.
McKesson (NYSE:MCK) will release its first quarter fiscal 2027 financial results after market close on Wednesday, August 5, 2026. Following the release, the company will host a live earnings conference call at 4:30 PM Eastern Time, accessible via its Investor Relations website.
McKesson (NYSE:MCK) closed a strategic minority investment with Apollo Funds in its Medical-Surgical Solutions (MMS) business on June 1, 2026. Apollo Funds invested $1.25 billion in convertible preferred equity for an approximately 13% interest, implying a $13 billion enterprise value for MMS. McKesson maintains majority ownership, operating control, and financial consolidation.
McKesson (NYSE: MCK) released its fiscal 2026 fourth-quarter results and is hosting a live earnings webcast and conference call today, May 7 at 4:30 PM ET.
According to McKesson, the audio webcast will be available live and archived on the company’s Investor Relations site, along with the earnings release, financial tables, and slide presentation.
McKesson (NYSE:MCK) declared a regular quarterly dividend of $0.82 per share. The Board approved the dividend, which is payable on July 1, 2026 to shareholders of record as of June 1, 2026.
McKesson (NYSE: MCK) agreed April 20, 2026 to sell an approximate 13% minority interest in its Medical-Surgical Solutions (MMS) business to funds managed by Apollo for $1.25 billion in convertible preferred equity, valuing MMS at about $13 billion enterprise value.
McKesson will retain majority ownership and operating control, continue to consolidate MMS results, and said the deal supports its planned separation and IPO; the transaction remains subject to regulatory approvals and customary closing conditions.
McKesson (NYSE: MCK) will release fourth quarter fiscal 2026 results after market close on Thursday, May 7, 2026, followed by a live investor webcast at 4:30 PM ET hosted by CEO Brian Tyler and CFO Britt Vitalone.
Mr. Vitalone will participate in the Leerink Partners and Barclays Global Healthcare Conferences on March 11, 2026 and the BofA Securities 2026 Healthcare Conference in May 2026. McKesson reaffirmed its fiscal 2026 full year outlook as previously issued on February 4, 2026. Webcasts will be available on McKesson’s investor website.